A study on the correlation between APOE gene polymorphism, white matter hyperintensities, and neuropsychiatric symptom phenotypes in Alzheimer’s disease - Report - MDSpire
Advertisement
A study on the correlation between APOE gene polymorphism, white matter hyperintensities, and neuropsychiatric symptom phenotypes in Alzheimer’s disease
APOE Genotype and White Matter Hyperintensities in Alzheimer’s Neuropsychiatric Symptoms
Overview
This study of 325 Alzheimer’s disease patients reveals that APOE ϵ4 homozygosity is linked to more severe cognitive decline and distinct neuropsychiatric symptoms, including delusions, agitation, irritability, and euphoria. Importantly, white matter hyperintensities do not mediate these associations, indicating direct effects of APOE genotype on symptomatology.
Background
Alzheimer’s disease (AD) is a leading cause of dementia characterized by cognitive deficits and nearly universal neuropsychiatric symptoms (NPS) such as hallucinations, delusions, and agitation. The APOE gene, particularly the ϵ4 allele, is a major genetic risk factor influencing AD onset and progression. White matter hyperintensities (WMH), markers of cerebral small vessel disease, have been implicated in cognitive decline and NPS but their role relative to APOE genotype remains unclear. Understanding how APOE variants and WMH contribute to NPS heterogeneity can improve prognostic and therapeutic strategies.
Data Highlights
APOE Genotype Group
CMMSE Score
ADL Score
Agitation Score
Delusions
Irritability
Euphoria
ϵ2/ϵ2–ϵ2/ϵ3
Higher (better)
Higher (better)
Lower
Lower
Lower
Lower
ϵ3/ϵ3
Intermediate
Intermediate
Lower
Lower
Lower
Lower
ϵ3/ϵ4
Lower
Lower
Higher
Intermediate
Intermediate
Intermediate
ϵ4/ϵ4
Lowest
Lowest
Highest
Highest
Highest
Highest
Key Findings
APOE ϵ4 carriers show significantly worse cognitive (CMMSE) and functional (ADL) scores compared to non-carriers (p < 0.05).
Patients homozygous for ϵ4 (ϵ4/ϵ4) exhibit the greatest severity in neuropsychiatric symptoms: delusions, agitation, irritability, and euphoria (all p < 0.05).
Agitation scores are higher in all ϵ4 carriers relative to non-carriers (p < 0.05).
Mediation analysis indicates no significant indirect effect of APOE genotype on cognition or NPS via WMH burden.
APOE genotype exerts robust direct effects on cognitive performance and specific neuropsychiatric symptom domains independent of WMH.
Clinical Implications
APOE genotyping, especially identifying ϵ4 homozygotes, can provide valuable prognostic information regarding both cognitive decline and neuropsychiatric symptom severity in AD patients. Since WMH burden does not mediate these effects, clinicians should consider APOE status as an independent biomarker to guide personalized management of behavioral symptoms. This may inform targeted interventions and caregiver support strategies beyond conventional neuroimaging assessments.
Conclusion
The APOE ϵ4 allele, particularly in homozygous form, is directly associated with more severe cognitive impairment and distinct neuropsychiatric symptom profiles in Alzheimer’s disease, independent of white matter hyperintensity burden. APOE genotyping thus offers dual clinical utility for risk stratification and behavioral prognosis.
References
Study Authors/2025 -- Exploring the Relationship Between APOE Gene Variants, White Matter Hyperintensities, and Neuropsychiatric Symptoms in Alzheimer’s Disease
